evaluate the pharmaceuticals company saxenda on glp-1 drugs for diabetes (liraglutide) Treatment of Obesity, US GLP-1 Market Trends and Global

In the UK, NICE recommends GLP-1 receptor agonists for type 2 diabetes in specific circumstances (NG28), such as when metformin is insufficient and BMI 30 kg/m

Metformin does not directly stimulate insulin release and has been a first-line diabetes treatment for over 50 years

These treatments are guided by licensed clinicians and tailored to your individual goals

Leaving aside their newly approved use for obesity, accelerated growth in the utilization of GLP-1s for diabetes had already made them a top trend driver over the past few years

18 September 2014

For research professionals, the practical implications are clear